{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:59:14Z","timestamp":1769122754636,"version":"3.49.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":2052,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although tolvaptan has been reported to prevent worsening renal function (WRF) in patients with advanced acute heart failure (AHF), evidence regarding the effect of tolvaptan on renal function in patients with new-onset AHF is not available. This study aimed to investigate the renoprotective effect of tolvaptan in patients hospitalized with new-onset AHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A total of 122 consecutive patients hospitalized with new-onset AHF between May 2015 and December 2018 were retrospectively evaluated. WRF was defined as an absolute increase in serum creatinine \u22650.3 mg\/dL (\u226526.4 \u03bcmol\/L) within 48 h or a 1.5-fold increase in serum creatinine after hospitalization. The furosemide group (n = 75) and the tolvaptan add-on group (n = 47) were compared. The tolvaptan group consists of patients who received tolvaptan as an individual physicians' decision. The incidence of WRF was significantly lower in the tolvaptan add-on group (8.5%) than in the furosemide group (24.0%, P = 0.03). Multivariate logistic regression analysis revealed that tolvaptan treatment was an independent variable related to the prevention of WRF [odds ratio (OR), 0.20; 95% confidence interval (CI), 0.05\u20130.85]. Furthermore, subgroup analysis revealed a more favourable effect of tolvaptan in patients with serum creatinine \u22651.1 mg\/dL on admission (OR, 0.23; 95% CI, 0.06\u20130.98) and an ejection fraction &amp;lt;50% (OR, 0.19; 95% CI, 0.04\u20130.90).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A lower incidence of WRF was observed in patients with new-onset AHF who were treated with the tolvaptan add-on therapy, specifically those with left ventricular systolic dysfunction and renal impairment on admission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12738","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T22:34:27Z","timestamp":1588890867000},"page":"1764-1770","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Renoprotective Effect of Tolvaptan in Patients with New-Onset Acute Heart Failure"],"prefix":"10.1093","volume":"7","author":[{"given":"Hiromi","family":"Kin","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-3505","authenticated-orcid":false,"given":"Koichiro","family":"Matsumura*","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munemitsu","family":"Otagaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haengnam","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Medical University Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Shiojima","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"2026012115035729100_ehf212738-bib-0001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J Card Fail"},{"key":"2026012115035729100_ehf212738-bib-0002","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.amjcard.2010.01.361","article-title":"Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure","volume":"105","author":"Kociol","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026012115035729100_ehf212738-bib-0003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012115035729100_ehf212738-bib-0004","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehv010","article-title":"The kidney in heart failure: an update","volume":"36","author":"Damman","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115035729100_ehf212738-bib-0005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1253\/circj.CJ-13-1255","article-title":"Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure","volume":"78","author":"Shirakabe","year":"2014","journal-title":"Circ J"},{"key":"2026012115035729100_ehf212738-bib-0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","article-title":"Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment\u2014results from the K-STAR study","volume":"82","author":"Inomata","year":"2017","journal-title":"Circ J"},{"key":"2026012115035729100_ehf212738-bib-0007","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure","volume":"67","author":"Kimura","year":"2016","journal-title":"J Cardiol"},{"key":"2026012115035729100_ehf212738-bib-0008","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction\u2014prospective randomized controlled study","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ J"},{"key":"2026012115035729100_ehf212738-bib-0009","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00380-018-1290-6","article-title":"Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment","volume":"34","author":"Matsumura","year":"2019","journal-title":"Heart Vessels"},{"key":"2026012115035729100_ehf212738-bib-0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828","article-title":"Decongestive therapy and renal function in acute heart failure: time for a new approach?","volume":"7","author":"Goldsmith","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026012115035729100_ehf212738-bib-0011","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/0735-1097(93)90455-A","article-title":"The epidemiology of heart failure: the Framingham study","volume":"22","author":"Ho","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035729100_ehf212738-bib-0012","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115035729100_ehf212738-bib-0013","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"2026012115035729100_ehf212738-bib-0014","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115035729100_ehf212738-bib-0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12947-019-0177-8","article-title":"Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review","volume":"17","author":"Matsumura","year":"2019","journal-title":"Cardiovasc Ultrasound"},{"key":"2026012115035729100_ehf212738-bib-0016","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12574-019-00448-7","article-title":"Comparison of transthoracic and transesophageal echocardiography for transcatheter aortic valve replacement sizing in high-risk patients","volume":"18","author":"Fox","year":"2020","journal-title":"J Echocardiogr"},{"key":"2026012115035729100_ehf212738-bib-0017","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","article-title":"Diuretic response in acute heart failure: clinical characteristics and prognostic significance","volume":"35","author":"Valente","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012115035729100_ehf212738-bib-0018","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1253\/circj.CJ-11-1500","article-title":"Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure","volume":"76","author":"Masuyama","year":"2012","journal-title":"Circ J"},{"key":"2026012115035729100_ehf212738-bib-0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","article-title":"Human experimentation. Code of Ethics of the World Medical Association Declaration of Helsinki","volume":"2","author":"Rickham","year":"1964","journal-title":"Br Med J"},{"key":"2026012115035729100_ehf212738-bib-0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2007.06.007","article-title":"Transient worsening of renal function during hospitalization for acute heart failure alters outcome","volume":"127","author":"Logeart","year":"2008","journal-title":"Int J Cardiol"},{"key":"2026012115035729100_ehf212738-bib-0021","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1253\/circj.CJ-12-0994","article-title":"Prognostic impact of acute kidney injury in patients with acute decompensated heart failure","volume":"77","author":"Shirakabe","year":"2013","journal-title":"Circ J"},{"key":"2026012115035729100_ehf212738-bib-0022","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","article-title":"Is worsening renal function an ominous prognostic sign in patients with acute heart failure? the role of congestion and its interaction with renal function","volume":"5","author":"Metra","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2026012115035729100_ehf212738-bib-0023","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/293938","article-title":"Cardiorenal syndrome in acute heart failure syndromes","volume":"2011","author":"Sarraf","year":"2011","journal-title":"Int J Nephrol"},{"key":"2026012115035729100_ehf212738-bib-0024","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jacc.2012.01.077","article-title":"Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure","volume":"60","author":"Ronco","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035729100_ehf212738-bib-0025","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012115035729100_ehf212738-bib-0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"2026012115035729100_ehf212738-bib-0027","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCHEARTFAILURE.114.001734","article-title":"Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction","volume":"8","author":"Takei","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026012115035729100_ehf212738-bib-0028","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/eurjhf\/hfs209","article-title":"Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment","volume":"15","author":"Dupont","year":"2013","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12738","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/4\/1764\/65901916\/eschf_7_4_1764.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/4\/1764\/65901916\/eschf_7_4_1764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:04:44Z","timestamp":1769025884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/4\/1764\/8372999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12738","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"2019-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}